These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22368149)

  • 21. [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
    Feng GX; Liang Y; Bai Y; Chen T; Liu X; Yang YM; Wang XY; Yang YJ; Zhu J
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 Nov; 40(11):908-13. PubMed ID: 23363670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach.
    Al-Azzam SI; Alzoubi KH; Khabour OF; Nusair MB; Al-Hadidi H; Awidi A; Saleh A
    Int J Clin Pharmacol Ther; 2013 Mar; 51(3):179-86. PubMed ID: 23357840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response.
    Lewis JP; Fisch AS; Ryan K; O'Connell JR; Gibson Q; Mitchell BD; Shen H; Tanner K; Horenstein RB; Pakzy R; Tantry US; Bliden KP; Gurbel PA; Shuldiner AR
    Clin Pharmacol Ther; 2011 Oct; 90(4):568-74. PubMed ID: 21881565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between
    Biswas M; Kali SK; Sarker AK; Sukasem C
    Expert Opin Drug Saf; 2023; 22(9):807-817. PubMed ID: 37148265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent clinical trial results with antiplatelet therapy: implications in stroke prevention.
    Teal PA
    Cerebrovasc Dis; 2004; 17 Suppl 3():6-10. PubMed ID: 14730252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical appraisal of the CURE trial: role of clopidogrel in non-ST-segment elevation acute coronary syndromes.
    Boucher M; Pharand C; Skidmore B
    Can J Clin Pharmacol; 2004; 11(1):e156-67. PubMed ID: 15300958
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M; Latsios G; Aggelis D; Bosinakou I; Karambelas I; Tousoulis D; Toutouzas K; Stefanadis C
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    Gerschutz GP; Bhatt DL;
    Am Heart J; 2003 Apr; 145(4):595-601. PubMed ID: 12679754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between paraoxonase-1 Q192R polymorphism and lung function among Saskatchewan grain handlers.
    Takayuki S; Pahwa P; McDuffie HH; Shindo J; Goto S; Hashimoto M; Ghosh S; Nakagawa K
    Pharmacogenomics; 2007 Aug; 8(8):901-8. PubMed ID: 17716225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy evaluation of clopidogrel compared to ticlopidine after stent implantation: an updated meta-analysis.
    Casella G; Ottani F; Pavesi PC; Sangiorgio P; Rubboli A; Galvani M; Fontanelli A; Bracchetti D
    Ital Heart J; 2003 Oct; 4(10):677-84. PubMed ID: 14664280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
    ; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
    Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial.
    Lamy A; Tong W; Gao P; Chrolavicius S; Gafni A; Yusuf S; Connolly SJ
    Can J Cardiol; 2012; 28(1):95-101. PubMed ID: 21983111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of paraoxonase polymorphism (Q192R) on endothelial function in intact coronary circulation.
    Yamane T; Matsumoto T; Nakae I; Takashima H; Tarutani Y; Tamaki S; Horie M
    Hypertens Res; 2006 Jun; 29(6):417-22. PubMed ID: 16940704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial.
    Hart RG; Bhatt DL; Hacke W; Fox KA; Hankey GJ; Berger PB; Hu T; Topol EJ;
    Cerebrovasc Dis; 2008; 25(4):344-7. PubMed ID: 18303254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum paraoxonase-1 (PON1) activities (PONase/AREase) and polymorphisms in patients with type 2 diabetes mellitus in a North-West Indian population.
    Gupta N; Binukumar BK; Singh S; Sunkaria A; Kandimalla R; Bhansali A; Gill KD
    Gene; 2011 Nov; 487(1):88-95. PubMed ID: 21803130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction.
    Morrow DA; Wiviott SD; White HD; Nicolau JC; Bramucci E; Murphy SA; Bonaca MP; Ruff CT; Scirica BM; McCabe CH; Antman EM; Braunwald E
    Circulation; 2009 Jun; 119(21):2758-64. PubMed ID: 19451347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
    Hirsh J; Bhatt DL
    Arch Intern Med; 2004 Oct; 164(19):2106-10. PubMed ID: 15505123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paraoxonase 1 gene polymorphism does not affect clopidogrel response variability but is associated with clinical outcome after PCI.
    Park KW; Park JJ; Kang J; Jeon KH; Kang SH; Han JK; Lee SE; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    PLoS One; 2013; 8(2):e52779. PubMed ID: 23418418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
    Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
    J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents.
    Calver AL; Blows LJ; Harmer S; Dawkins KD; Gray HH; Morgan JH; Simpson IA
    Am Heart J; 2000 Sep; 140(3):483-91. PubMed ID: 10966552
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.